Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(2), P. 260 - 260
Published: Feb. 19, 2024
Although
a
lot
of
effort
has
been
put
into
creating
drugs
and
combination
therapies
against
chronic
hepatitis,
no
effective
treatment
established.
Type-I
interferon
is
promising
therapeutic
for
hepatitis
due
to
its
excellent
anti-inflammatory
effects
through
receptors
on
hepatic
macrophages.
To
develop
type-I
IFN
equipped
with
the
ability
target
macrophages
macrophage
mannose
receptor,
present
study
designed
mouse
interferon-mannosylated
albumin
fusion
protein
using
site-specific
mutagenesis
technology.
This
exhibited
induction
molecules,
such
as
IL-10,
IL-1Ra,
PD-1,
in
RAW264.7
cells,
or
hepatoprotective
carbon
tetrachloride-induced
mice.
As
expected,
biological
actions
were
significantly
superior
those
human
proteins.
Furthermore,
repeated
administration
mice
clearly
suppressed
area
liver
fibrosis
hydroxyproline
contents,
not
only
reduction
levels
inflammatory
cytokine
(TNF-α)
fibrosis-related
genes
(TGF-β,
Fibronectin,
Snail,
Collagen
1α2),
but
also
shift
phenotype
from
anti-inflammatory.
Therefore,
potential
new
agent
hepatitis.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Sept. 6, 2024
Cancer-associated
fibroblasts
(CAFs)
are
abundant
and
influential
elements
of
the
tumor
microenvironment
(TME),
giving
support
to
development
in
multiple
ways.
Among
other
mechanisms,
CAFs
important
regulators
immunological
processes
occurring
tumors.
However,
CAF-mediated
immunomodulation
context
radiotherapy
remains
poorly
understood.
In
this
study,
we
explore
effects
radiation
on
CAF-derived
immunoregulatory
signals
TME.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(21), P. 3671 - 3671
Published: Oct. 30, 2024
The
gut
microbiome
has
emerged
as
a
crucial
player
in
modulating
cancer
therapies,
including
radiotherapy.
In
the
case
of
breast
cancer,
interplay
between
and
radiotherapy-derived
metabolites
may
enhance
therapeutic
outcomes
minimize
adverse
effects.
this
review,
we
explore
bidirectional
relationship
cancer.
We
explain
how
composition
influences
progression
treatment
response,
its
treatments
influence
composition.
A
dual
role
for
is
explored
article,
highlighting
both
their
benefits
potential
hazards.
By
integrating
genomics,
metabolomics,
bioinformatics
tools,
present
comprehensive
overview
these
interactions.
study
provides
real-world
insight
through
studies
clinical
trials,
while
innovations
such
probiotics,
dietary
interventions
are
examined
to
modulate
effectiveness.
Moreover,
ethical
considerations
patient
perspectives
discussed,
ensuring
understanding
subject.
Towards
revolutionizing
strategies
improving
outcomes,
review
concludes
with
future
research
directions.
It
also
envisions
metabolite
into
personalized
therapy.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(2), P. 260 - 260
Published: Feb. 19, 2024
Although
a
lot
of
effort
has
been
put
into
creating
drugs
and
combination
therapies
against
chronic
hepatitis,
no
effective
treatment
established.
Type-I
interferon
is
promising
therapeutic
for
hepatitis
due
to
its
excellent
anti-inflammatory
effects
through
receptors
on
hepatic
macrophages.
To
develop
type-I
IFN
equipped
with
the
ability
target
macrophages
macrophage
mannose
receptor,
present
study
designed
mouse
interferon-mannosylated
albumin
fusion
protein
using
site-specific
mutagenesis
technology.
This
exhibited
induction
molecules,
such
as
IL-10,
IL-1Ra,
PD-1,
in
RAW264.7
cells,
or
hepatoprotective
carbon
tetrachloride-induced
mice.
As
expected,
biological
actions
were
significantly
superior
those
human
proteins.
Furthermore,
repeated
administration
mice
clearly
suppressed
area
liver
fibrosis
hydroxyproline
contents,
not
only
reduction
levels
inflammatory
cytokine
(TNF-α)
fibrosis-related
genes
(TGF-β,
Fibronectin,
Snail,
Collagen
1α2),
but
also
shift
phenotype
from
anti-inflammatory.
Therefore,
potential
new
agent
hepatitis.
